Eric Pauwels serves as the Chief Business Officer at PTC Therapeutics Inc., a biopharmaceutical company focused on the discovery, development, and commercialization of innovative treatments for rare disorders. In his role, Pauwels is responsible for overseeing the company's business development strategies, including partnerships, licensing agreements, and mergers and acquisitions. His leadership has been instrumental in expanding PTC's pipeline and strengthening its position in the rare disease market. Before joining PTC Therapeutics, Pauwels had an extensive career in the pharmaceutical and biotechnology industries. He held various senior leadership positions at companies such as Alexion Pharmaceuticals, where he served as Senior Vice President of Business Development, and Novartis, where he worked in multiple capacities, including as Global Head of Business Development and Licensing for the Pharmaceuticals Division. Throughout his career, Pauwels has been recognized for his ability to forge strategic partnerships and drive growth through innovative collaborations. Pauwels' contributions to PTC Therapeutics have been significant, particularly in the areas of business expansion and portfolio diversification. Under his guidance, the company has secured several key partnerships and licensing deals that have enhanced its research and development capabilities. His strategic vision and deep understanding of the industry have been vital in positioning PTC as a leader in the development of treatments for rare diseases. Pauwels holds a Master of Science degree in Biotechnology from the University of Ghent and an MBA from the Vlerick Business School in Belgium.